Policy & Regulation
Tevogen Bio submits Investigational New Drug application for COVID-19 treatment development
15 October 2020 -

Tevogen Bio, a clinical stage biotechnology company, has submitted its Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for the development of COVID-19 treatment using proprietary antigen specific T cell technology, it was reported on Wednesday.

The company is collaborating with bone marrow transplant expert, Dr Neal Flomenberg, chair of the Department of Medical Oncology at Thomas Jefferson University, with the aim of assessing the company's T cell technology to treat hospitalised COVID-19 patients.

The partnership intends to use Tevogen's proprietary immunotherapy platform and Dr Flomenberg's expertise in research and the transplantation of T cells so that both can conduct clinical trials of T cell treatments for COVID-19. In the proposed trials, T cells will be generated in the laboratory and administered to those patients in the COVID-19 spectrum that are most ill.



Related Headlines